Brinuspry
Asset
Inhibits dipeptidyl peptidase 1, reducing activation of neutrophil serine proteases and associated inflammation.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Inflammation
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Non-cystic fibrosis bronchiectasis
Approved, answers.and-pro.jp, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets1
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.